TY  - JOUR
Y1  - 2025/10/30/
AV  - public
A1  - Amonova N, Amonova N
A1  - Umurova N, Umurova N
VL  - 2
ID  - arxiv97350
UR  - https://universalconference.us/index.php/icmse/article/view/5639
IS  - 9
N2  - Metabolic syndrome (MS) combined with type 2 diabetes mellitus (T2DM) is one of the most urgent global health problems. It represents a cluster of metabolic and cardiovascular disorders such as abdominal obesity, hypertension, hyperglycemia, dyslipidemia, and insulin resistance [1?3]. The coexistence of MS and T2DM markedly increases the risk of cardiovascular events, nephropathy, and non-alcoholic fatty liver disease. According to IDF and WHO data, the prevalence of MS among diabetic patients reaches 60?80%, emphasizing the need for comprehensive therapeutic strategies to improve metabolic control and prevent complications.
TI  - METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: CLINICAL FEATURES, METABOLIC DISORDERS AND APPROACHES TO CORRECTION
JF  - INTERNATIONAL CONFERENCE ON MEDICINE, SCIENCE, AND EDUCATION
ER  -